A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

This trial is testing AK112 — a drug that simultaneously blocks both PD-1 (immune checkpoint) and VEGF (tumor blood supply) — combined with chemotherapy in patients with stage IV non-squamous non-small cell lung cancer (NSCLC) that has spread to the lining around the lungs (malignant pleural effusion). **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with stage IV non-squamous NSCLC confirmed by biopsy - Your cancer has spread to the pleural space around the lungs (malignant pleural effusion confirmed by cytology or imaging) - Your cancer does not have known driver gene mutations (such as EGFR, ALK, ROS1) - Your general health is good (ECOG score 0-2) with adequate organ function **You may NOT be eligible if...** - Your lung cancer has a targetable driver mutation for which a specific approved therapy exists - You have already received systemic treatment for advanced NSCLC - You have active or poorly controlled autoimmune disease - Your lung or organ function is too compromised to handle chemotherapy Talk to your doctor to see if this trial is right for you.